Cargando…

Impact of metformin on statin‐associated myopathy risks in dyslipidemia patients

A growing number of patients with metabolic disorders are receiving statin and antidiabetic therapies as comedications. A signal of increased risk of myotoxicity due to potential interactions between antidiabetics and statins has been detected in previous studies. To investigate the effects of metfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bak, Keunhyeong, Moon, Suhyeon, Ko, Minjung, Choi, Yeo Jin, Shin, Sooyoung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327420/
https://www.ncbi.nlm.nih.gov/pubmed/37417539
http://dx.doi.org/10.1002/prp2.1114
_version_ 1785069622492397568
author Bak, Keunhyeong
Moon, Suhyeon
Ko, Minjung
Choi, Yeo Jin
Shin, Sooyoung
author_facet Bak, Keunhyeong
Moon, Suhyeon
Ko, Minjung
Choi, Yeo Jin
Shin, Sooyoung
author_sort Bak, Keunhyeong
collection PubMed
description A growing number of patients with metabolic disorders are receiving statin and antidiabetic therapies as comedications. A signal of increased risk of myotoxicity due to potential interactions between antidiabetics and statins has been detected in previous studies. To investigate the effects of metformin on myopathy risks when added to preexisting statin therapy in dyslipidemia patients, we performed a retrospective cohort study using the Korean national health insurance data in statin‐treated dyslipidemia patients with or without concomitant metformin use. We compared the risk of myopathy in statin + metformin users against statin‐only users. Hazard ratios (HRs) and 95% confidence intervals (CIs) have been calculated following propensity score (PS) matching between study groups and subsequent stratification per patient factors. We included 4092 and 8161 patients in PS‐matched statin + metformin and statin‐only groups, respectively. The risk of myopathy decreased when metformin was used together with statins (adjusted HR 0.84; 95% CI 0.71–0.99). In subgroup analyses per individual statin agent and in stratified risk analyses, no specific statin agents or patient factors were associated with statistically significant myopathy risk. This study found that a comedication with metformin was associated with decreased myopathy risk in statin‐treated dyslipidemia patients compared to statin‐only users. Our findings suggest that metformin may provide protective effects on potential muscle toxicities induced by statin therapy.
format Online
Article
Text
id pubmed-10327420
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-103274202023-07-08 Impact of metformin on statin‐associated myopathy risks in dyslipidemia patients Bak, Keunhyeong Moon, Suhyeon Ko, Minjung Choi, Yeo Jin Shin, Sooyoung Pharmacol Res Perspect Original Articles A growing number of patients with metabolic disorders are receiving statin and antidiabetic therapies as comedications. A signal of increased risk of myotoxicity due to potential interactions between antidiabetics and statins has been detected in previous studies. To investigate the effects of metformin on myopathy risks when added to preexisting statin therapy in dyslipidemia patients, we performed a retrospective cohort study using the Korean national health insurance data in statin‐treated dyslipidemia patients with or without concomitant metformin use. We compared the risk of myopathy in statin + metformin users against statin‐only users. Hazard ratios (HRs) and 95% confidence intervals (CIs) have been calculated following propensity score (PS) matching between study groups and subsequent stratification per patient factors. We included 4092 and 8161 patients in PS‐matched statin + metformin and statin‐only groups, respectively. The risk of myopathy decreased when metformin was used together with statins (adjusted HR 0.84; 95% CI 0.71–0.99). In subgroup analyses per individual statin agent and in stratified risk analyses, no specific statin agents or patient factors were associated with statistically significant myopathy risk. This study found that a comedication with metformin was associated with decreased myopathy risk in statin‐treated dyslipidemia patients compared to statin‐only users. Our findings suggest that metformin may provide protective effects on potential muscle toxicities induced by statin therapy. John Wiley and Sons Inc. 2023-07-07 /pmc/articles/PMC10327420/ /pubmed/37417539 http://dx.doi.org/10.1002/prp2.1114 Text en © 2023 The Authors. Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Bak, Keunhyeong
Moon, Suhyeon
Ko, Minjung
Choi, Yeo Jin
Shin, Sooyoung
Impact of metformin on statin‐associated myopathy risks in dyslipidemia patients
title Impact of metformin on statin‐associated myopathy risks in dyslipidemia patients
title_full Impact of metformin on statin‐associated myopathy risks in dyslipidemia patients
title_fullStr Impact of metformin on statin‐associated myopathy risks in dyslipidemia patients
title_full_unstemmed Impact of metformin on statin‐associated myopathy risks in dyslipidemia patients
title_short Impact of metformin on statin‐associated myopathy risks in dyslipidemia patients
title_sort impact of metformin on statin‐associated myopathy risks in dyslipidemia patients
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327420/
https://www.ncbi.nlm.nih.gov/pubmed/37417539
http://dx.doi.org/10.1002/prp2.1114
work_keys_str_mv AT bakkeunhyeong impactofmetforminonstatinassociatedmyopathyrisksindyslipidemiapatients
AT moonsuhyeon impactofmetforminonstatinassociatedmyopathyrisksindyslipidemiapatients
AT kominjung impactofmetforminonstatinassociatedmyopathyrisksindyslipidemiapatients
AT choiyeojin impactofmetforminonstatinassociatedmyopathyrisksindyslipidemiapatients
AT shinsooyoung impactofmetforminonstatinassociatedmyopathyrisksindyslipidemiapatients